Study Confirms That Steroids Save Very Ill COVID Patients
September 3, 2020
By Neozene

The following article originally appeared in FiercePharma and was written by Angus Liu When researchers in the U.K. said in June that the low-cost corticosteroid dexamethasone could reduce death rates in critically ill COVID-19 patients, clinicians still had doubts about whether to change their treatment practice without full data. But findings from a series of clinical trials from around the world, along with a new meta-analysis—all of which were published on Wednesday in JAMA—will likely change that. The findings “provide definitive data that corticosteroids should be first-line treatment for critically ill patients

Read More

Analyst: Moderna COVID-19 Vaccine Outlook Too Rosy
August 27, 2020
By Neozene

The following article originally appeared in FiercePharma and was written by Angus Liu Moderna’s mRNA COVID-19 vaccine candidate was the first U.S. shot to enter late-stage testing, but that doesn’t necessarily mean it has the brightest future of all. The high possibility of multiple emergency authorizations for coronavirus vaccines by year-end spells plenty of competition—and an outlook for Moderna that’s less rosy than expected, SVB Leerink analyst Geoffrey Porges and his team wrote in an investor note, citing R&D and vaccine experts. “[E]arlier entry of another large, established global pharma competitor

Read More

Two Pharma Giants Join Forces to Triple Manufacturing of COVID-19 Antibody Cocktail
August 19, 2020
By Neozene

This article originally appeared in FiercePharma and was written by Kyle Blankenship Despite hundreds of potential therapies for COVID-19 looking to make their case, very few have crossed the finish line. One promising candidate, Regeneron’s two-antibody cocktail, has earned early plaudits—and now a pharma giant is jumping aboard to boost manufacturing in a big way. Regeneron will team up with Swiss drugmaker Roche to more than triple production of the New York biotech’s COVID-19 antibody therapy, REGN-COV2, for a planned global rollout, the partners said Wednesday. Under a seven-year licensing

Read More